RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Avidity Biosciences, Inc. to Novartis for $72.00 per share in cash, raising concerns about whether shareholders are receiving adequate value for their shares [1][3]. Group 1: Investigation Details - The investigation focuses on whether Avidity and its board violated federal securities laws and fiduciary duties by not obtaining the best possible consideration for shareholders [3]. - Key concerns include whether Novartis is underpaying for Avidity and whether all material information necessary for shareholders to assess the merger has been disclosed [3]. Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [4].